ClinicalTrials.gg
CompletedNCT03587207Updated Feb 12, 2020Results posted

Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years

A Phase 2 interventional study of MenABCWY vaccine and rMenB+OMV NZ (Bexsero) vaccine in Meningitis, Meningococcal, sponsored by GlaxoSmithKline. Completed at 1 site in Czechia. Open to participants aged 10 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-12.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
520
Allocation
Randomized
Ages
10 Years to 25 Years
Sex
All
01

Study summary

The purpose of the current study is to evaluate whether there is immune interference when MenABCWY [consisting of MenACWY lyophilized component and rMenB+OMV NZ (Bexsero) liquid component] is administered to healthy adolescents and adults following a 2-dose vaccination schedule with MenABCWY administered 2 months apart.

02

Conditions studied

  • Meningitis, Meningococcal

Keywords

  • Meningitis
  • Concomitantly
  • Adolescent
  • Neisseria meningitidis
  • Healthy subjects
  • Adult
03

In context

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

This study's enrollment of 520 is close to the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.

Browse Meningitis, Meningococcal studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 117 are open to participants now.

Of its 268 completed or terminated interventional studies of FDA-regulated products, 242 (90%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects and/or subjects' parent(s)/Legally Acceptable Representative(s) (LARs) who, in the opinion of the investigator, can and will comply, with the requirements of the protocol (e.g. completion of the paper diary (pDiary), return for follow-up visits, availability for all visits scheduled in the study).
  • Written obtained from the subject and/or from the parent(s)/LAR(s) of the subject prior to performing any study specific procedure.
  • Written informed assent obtained from subjects below the legal age of consent prior to performing any study specific procedure.
  • A male or female between, and including, 10 to 25 years of age at the time of the first vaccination.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • Female subjects of non- may be enrolled in the study.

    • Non-childbearing potential is defined as pre menarche, current bilateral tubal ligation or occlusion, hysterectomy, or bilateral ovariectomy.
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced highly effective for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue highly effective contraception during the entire treatment period and for 2 months after completion of the vaccination series.

Exclusion criteria

Exclusion Criteria:

  • Female planning to become pregnant or planning to discontinue precautions
  • Pregnant or lactating female
  • Child in care
  • Current or previous, confirmed or suspected disease caused by N. meningitidis.
  • Known contact to an individual with any laboratory confirmed N. meningitidis infection within 60 days prior to enrolment.
  • Previous vaccination against N. meningitidis at any time prior to .
  • Progressive, unstable or uncontrolled clinical conditions.
  • , including allergy, to any component of vaccines, medicinal products or medical equipment whose use is foreseen in this study.
  • Clinical conditions representing a to IM vaccination and blood draws.
  • Abnormal function of the immune system resulting from:

    • Clinical conditions.
    • Systemic administration of (oral/intravenous/IM) for more than 14 consecutive days within 90 days prior to informed consent.
    • Administration of antineoplastic and immune modulating agents or radiotherapy within 90 days prior to informed consent.
  • Received immunoglobulins or any blood products within 180 days prior to informed consent.
  • Received an or non registered medicinal product within 30 days prior to informed consent.
  • Any other clinical condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non investigational vaccine/product.
  • Acute or chronic, pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by physical examination.
  • Any confirmed or suspected or immunodeficient condition, based on medical history and physical examination.
  • Are obese at screening.
  • Family history of congenital or hereditary immunodeficiency.
  • History of neuroinflammatory or condition.
  • History of significant neurological disorder or seizure.
  • Serious chronic illness.
  • History of chronic alcohol consumption and/or drug abuse.
  • Any study personnel as an immediate family or household member.
  • Administration of a vaccine not foreseen by the study protocol in the period starting 14 days (for inactivated vaccines), 28 days (for ), or 7 days (for influenza vaccines) before each dose and ending 14 days (for inactivated vaccines), 28 days (for live vaccines), or 7 days (for influenza vaccines) after each dose of study vaccine(s) administration.
  • Thrombocytopenia, bleeding disorders, or be receiving anticoagulant therapy.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
520 participants (actual)

Study arms

  • Experimental
    MenABCWY Group

    Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of MenABCWY twice, 2 months apart (Day 1 and Day 61).

    Biological: MenABCWY vaccine

  • Active comparator
    rMenBOMV+ACWY_S Group

    Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) concomitantly received one dose of rMenB+OMV NZ (Bexsero) and one dose of MenACWY (Menveo) in the same arm twice, 2 months apart (Day 1 and Day 61).

    Biological: rMenB+OMV NZ (Bexsero) vaccine · Biological: MenACWY (Menveo) vaccine

  • Active comparator
    rMenBOMV+ACWY_D Group

    Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) concomitantly received one dose of rMenB+OMV NZ (Bexsero) and one dose of MenACWY (Menveo) in 2 different arms twice, 2 months apart (Day 1 and Day 61).

    Biological: rMenB+OMV NZ (Bexsero) vaccine · Biological: MenACWY (Menveo) vaccine

  • Active comparator
    rMenBOMV Group

    Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of rMenB+OMV NZ (Bexsero) twice, 2 months apart (Day 1 and Day 61).

    Biological: rMenB+OMV NZ (Bexsero) vaccine

  • Active comparator
    MenACWY Group

    Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of MenACWY (Menveo) once at Day 1, which was the first and last vaccination for MenACWY group.

    Biological: MenACWY (Menveo) vaccine

Interventions

  • BiologicalMenABCWY vaccine

    Two doses administered intramuscularly in the deltoid region of the non-dominant arm.

  • BiologicalrMenB+OMV NZ (Bexsero) vaccine

    Drug page: 4CMenB vaccineStudies of 4CMenB vaccine4CMenB vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Two doses administered 2 months apart intramuscularly in the deltoid region of the non-dominant arm to subjects randomised to the rMenBOMV+ACWY_S Group, rMenBOMV+ACWY_D Group and rMenBOMV Group

  • BiologicalMenACWY (Menveo) vaccine

    Two doses administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the rMenBOMV+ACWY_S Group and rMenBOMV+ACWY_D Group and one dose administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the MenACWY Group

06

What researchers measure

Primary outcomes

  1. Human Serum Bactericidal Activity (hSBA) Adjusted Geometric Mean Titers (GMTs) Against All of N. Meningitidis Serogroup B Test Strains (Pooled), One Month After Last Vaccination.

    hSBA titers against all of N. meningitidis serogroup B test strains were calculated in terms of GMTs. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). The serogroup B strains were grouped together to perform a pooled analysis. Adjusted means were obtained from ANCOVA model fitted to all of the Serogroup B test strains, study group, test strain and center as fixed effects; zero-centered pre-vaccination log-transformed titer was included as a continuous covariate.

    Time frame: 1 month after last vaccination i.e.: at Day 91 for all groups except for the MenACWY Group

  2. hSBA Adjusted GMTs Against Each of the N. Meningitidis Serogroup B Test Strains and N. Meningitidis Serogroups A, C, W-135, and Y, One Month After Last Vaccination.

    hSBA titers against each of the N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y were calculated in terms of GMTs. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). Adjusted means were obtained from ANCOVA model fitted to each Serogroup (Strain) individually, study group and center as fixed effects and zero-centered pre-vaccination log-transformed titer as a continuous covariate.

    Time frame: 1 month after last vaccination i.e.: at Day 91 for all groups except the MenACWY Group, and at Day 31 for the MenACWY Group.

  3. Percentage of Subjects With hSBA Titers Greater Than or Equal to(≥) the Lower Limit of Quantitation (LLOQ) Against Each of the N. Meningitidis Serogroup B Test Strains and Serogroups A, C, W-135 and Y,One Month After Last Vaccination.

    Immune responses against N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y, were calculated in terms of percentage of subjects with hSBA titers ≥ LLOQ. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA).

    Time frame: 1 month after last vaccination i.e.: at Day 91 for all groups except the MenACWY Group, and at Day 31 for the MenACWY Group.

  4. Percentage of Subjects With a 4-fold Increase in hSBA Titers Against Each of the N. Meningitidis Serogroup B Test Strains and Against N. Meningitidis Serogroups A, C, W-135 and Y, One Month After Last Vaccination.

    Immune responses against N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y, were calculated in terms of percentage of subjects with a 4-fold increase in hSBA titers. A 4-fold rise was defined as: a) for individuals whose pre-vaccination titers were less than (\<) the limit of detection (LOD), the post-vaccination titers must have been ≥4-fold the LOD or ≥ the LLOQ, whichever was greater; b) for individuals whose pre-vaccination titers were ≥ the LOD and less than (\<) the LLOQ, the post-vaccination titers must have been at least 4 times the LLOQ; and c) for individuals whose pre-vaccination titers were ≥ the LLOQ, the post-vaccination titers must have been at least 4 times the pre-vaccination titer. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA).

    Time frame: 1 month after last vaccination versus baseline (i.e.: at Day 91 versus Day 1 for all groups except the MenACWY Group, and at Day 31 versus Day 1 for the MenACWY Group).

  5. hSBA Adjusted Geometric Mean Ratios (GMRs) Against Each of the N. Meningitidis Serogroup B Test Strains and Against N. Meningitidis Serogroups A, C, W-135 and Y, One Month After Last Vaccination.

    hSBA mean ratios at 1 month after the last vaccination versus baseline were calculated in terms of GMRs i.e. as the anti-logarithm of the mean of the change from baseline of log-transformed titer values at 1 month after last vaccination and Baseline. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). Adjusted means were obtained from ANCOVA model fitted to each Serogroup (Strain) individually, study group and center as fixed effects and zero-centered pre-vaccination log-transformed titer as a continuous covariate.

    Time frame: 1 month after last vaccination versus baseline (i.e.: at Day 91 versus Day 1 for all groups except the MenACWY Group, and at Day 31 versus Day 1 for the MenACWY Group).

Secondary outcomes

  1. hSBA Adjusted GMTs Against All of N. Meningitidis Serogroup B Test Strains (Pooled), One Month After First Vaccination

    hSBA titers against all of N. meningitidis serogroup B test strains were calculated in terms of GMTs. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). The serogroup B strains were grouped together to perform a pooled analysis. Adjusted means were obtained from ANCOVA model fitted to all of the Serogroup B test strains, study group, test strain and center as fixed effects; zero-centered pre-vaccination log-transformed titer was included as a continuous covariate.

    Time frame: 1 month after first vaccination i.e.: at Day 31 for all groups except for the MenACWY Group

  2. hSBA Adjusted GMTs Against Each of the N. Meningitidis Serogroup B Test Strains and N. Meningitidis Serogroups A, C, W-135 and Y, One Month After First Vaccination.

    hSBA titers against each of the N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y were calculated in terms of GMTs. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). Adjusted means were obtained from ANCOVA model fitted to each Serogroup (Strain) individually, study group and center as fixed effects and zero-centered pre-vaccination log-transformed titer as a continuous covariate.

    Time frame: 1 month after first vaccination i.e.: at Day 31 for all groups except for the MenACWY Group.

  3. Percentage of Subjects With hSBA Titers Greater Than or Equal to (≥) the LLOQ Against Each of the N. Meningitidis Serogroup B Test Strains and Against Serogroups A, C, W-135, and Y, One Month After First Vaccination

    Immune responses against N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y, were calculated in terms of percentage of subjects with hSBA titers ≥ LLOQ. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA).

    Time frame: 1 month after first vaccination i.e.: at Day 31 for all groups except for the MenACWY Group

  4. Percentage of Subjects With a 4-fold Increase in hSBA Titers Against Each of the N. Meningitidis Serogroup B Test Strains and Against N. Meningitidis Serogroups A, C, W-135, and Y, One Month After First Vaccination

    Immune responses against N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y, were calculated in terms of percentage of subjects with a 4-fold increase in hSBA titers. A 4-fold rise is defined as: a) for individuals whose pre-vaccination titers were less than (\<) the limit of detection (LOD), the post-vaccination titers must have been ≥4-fold the LOD or ≥ the LLOQ, whichever was greater; b) for individuals whose pre-vaccination titers were ≥ the LOD and less than (\<) the LLOQ, the post-vaccination titers must have been at least 4 times the LLOQ; and c) for individuals whose pre-vaccination titers were ≥ the LLOQ, the post-vaccination titers must have been at least 4 times the pre-vaccination titer. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA).

    Time frame: 1 month after first vaccination versus baseline (i.e.: at Day 31 versus Day 1 for all groups except for the MenACWY Group)

  5. hSBA Adjusted GMRs Against Each of the N. Meningitidis Serogroup B Test Strains and Against N. Meningitidis Serogroups A, C, W-135, and Y, One Month After First Vaccination

    hSBA mean ratios at 1 month after the first vaccination versus baseline were calculated in terms of GMRs. i.e. as the anti-logarithm of the mean of the change from baseline of log-transformed titer values at 1 month after first vaccination and Baseline. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). Adjusted mean were obtained from ANCOVA model fitted to each Serogroup (Strain) individually, study group and center as fixed effects and zero-centered pre-vaccination log-transformed titer as a continuous covariate.

    Time frame: 1 month after first vaccination versus baseline (i.e.: at Day 31 versus Day 1 for all groups except for the MenACWY Group)

  6. Number of Subjects With Any Solicited Local Adverse Events (AEs)

    Assessed local AEs were erythema, swelling, induration and pain. Any erythema, swelling and induration is defined as a symptom with a surface diameter equal to or greater than 25 millimeters.

    Time frame: During the 7 days (including the day of vaccination) after each vaccination i.e after Dose 1 administered at Day 1 (for all groups) and after Dose 2 administered at Day 61 (for all groups except for MenACWY Group)

  7. Number of Subjects With Any Solicited Systemic AEs

    Assessed systemic AEs were arthralgia, fatigue, nausea, headache, myalgia and fever. Any fever is defined as body temperature equal or greater than 38 degrees Celsius.

    Time frame: During the 7 days (including the day of vaccination) after each vaccination i.e after Dose 1 administered at Day 1 (for all groups) and after Dose 2 administered at Day 61 (for all groups except for MenACWY Group)

  8. Number of Subjects With Unsolicited AEs

    An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse. An unsolicited AE is an AE that was not solicited using a Subject Diary and that was spontaneously communicated by a subjects/parent(s)/ Legally Acceptable Representative who has signed the informed consent or a solicited local or systemic adverse event that continues beyond the solicited period at day 7 after vaccination.

    Time frame: During the 30 days (including the day of vaccination) after each vaccination i.e after Dose 1 administered at Day 1 (for all groups) and after Dose 2 administered at Day 61 (for all groups except for MenACWY Group)

  9. Number of Subjects With Serious Adverse Events (SAEs), Medically Attended AEs (MAEs), AEs Leading to Withdrawal, and Adverse Events of Special Interest (AESIs)

    SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity or was a congenital anomaly/birth defect in the offspring of a study subject. Medically attended AEs are defined as symptoms or illnesses requiring hospitalization, or emergency room visit, or visit to/by a health care provider. AESIs are predefined (serious or non-serious) adverse events of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterize and understand it.

    Time frame: During the whole study period i.e from Day 1 to Day 91

07

Results

Posted Jan 2, 2020

Participant flow

Subjects were recruited from 1 center at Czechia.

Participant flow — Overall Study
MilestoneMenABCWY GrouprMenBOMV+ACWY_S GrouprMenBOMV+ACWY_D GrouprMenBOMV GroupMenACWY Group
Started10010410094102
Completed10010410094102
Not completed00000

Outcome measures

PrimaryHuman Serum Bactericidal Activity (hSBA) Adjusted Geometric Mean Titers (GMTs) Against All of N. Meningitidis Serogroup B Test Strains (Pooled), One Month After Last Vaccination.

hSBA titers against all of N. meningitidis serogroup B test strains were calculated in terms of GMTs. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). The serogroup B strains were grouped together to perform a pooled analysis. Adjusted means were obtained from ANCOVA model fitted to all of the Serogroup B test strains, study group, test strain and center as fixed effects; zero-centered pre-vaccination log-transformed titer was included as a continuous covariate.

Time frame:
1 month after last vaccination i.e.: at Day 91 for all groups except for the MenACWY Group
Reported as:
Geometric mean · titers
Human Serum Bactericidal Activity (hSBA) Adjusted Geometric Mean Titers (GMTs) Against All of N. Meningitidis Serogroup B Test Strains (Pooled), One Month After Last Vaccination.
titersMenABCWY GrouprMenBOMV+ACWY_S GrouprMenBOMV+ACWY_D GrouprMenBOMV Group
Human Serum Bactericidal Activity (hSBA) Adjusted Geometric Mean Titers (GMTs) Against All of N. Meningitidis Serogroup B Test Strains (Pooled), One Month After Last Vaccination.31.84 (28.18 to 35.98)38.48 (34.23 to 43.26)40.08 (35.44 to 45.33)42.38 (37.31 to 48.13)
Statistical analysis
  • rMenBOMV+ACWY_S Group vs rMenBOMV+ACWY_D Group · ANCOVA · Geometric mean ratio: 0.96 · 80% CI 0.83 to 1.10An interaction between strain and pre-vaccination log transformed titer is included in the model to fit to the serogroup B test strain data only.
PrimaryhSBA Adjusted GMTs Against Each of the N. Meningitidis Serogroup B Test Strains and N. Meningitidis Serogroups A, C, W-135, and Y, One Month After Last Vaccination.

hSBA titers against each of the N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y were calculated in terms of GMTs. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). Adjusted means were obtained from ANCOVA model fitted to each Serogroup (Strain) individually, study group and center as fixed effects and zero-centered pre-vaccination log-transformed titer as a continuous covariate.

Time frame:
1 month after last vaccination i.e.: at Day 91 for all groups except the MenACWY Group, and at Day 31 for the MenACWY Group.
Reported as:
Geometric mean · titers
hSBA Adjusted GMTs Against Each of the N. Meningitidis Serogroup B Test Strains and N. Meningitidis Serogroups A, C, W-135, and Y, One Month After Last Vaccination.
titersMenABCWY GrouprMenBOMV+ACWY_S GrouprMenBOMV+ACWY_D GrouprMenBOMV GroupMenACWY Group
Meningitis B M14459 (fHbp)23.91 (20.52 to 27.86)23.34 (20.16 to 27.01)23.23 (19.91 to 27.10)22.87 (19.52 to 26.80)2.48 (2.13 to 2.89)
Meningitis B 96217(NadA)81.09 (69.24 to 94.97)102.68 (88.24 to 119.50)97.54 (83.18 to 114.39)113.54 (96.25 to 133.93)4.15 (3.54 to 4.86)
Meningitis B NZ98/254(PorA)12.97 (10.89 to 15.45)16.39 (13.86 to 19.39)21.12 (17.71 to 25.18)20.97 (17.47 to 25.16)2.15 (1.81 to 2.57)
Meningitis B M07-0241084(NHBA)13.08 (11.09 to 15.43)18.00 (15.35 to 21.11)22.59 (19.12 to 26.69)25.34 (21.30 to 30.13)4.08 (3.45 to 4.82)
Meningitis A104.90 (87.02 to 126.47)187.52 (156.94 to 224.05)204.01 (169.06 to 246.18)94.91 (78.26 to 115.12)52.03 (43.01 to 62.95)
Meningitis C172.99 (140.43 to 213.09)144.80 (118.48 to 176.97)145.42 (117.91 to 179.34)32.01 (25.75 to 39.79)34.66 (28.09 to 42.78)
Meningitis W260.11 (219.31 to 308.51)245.63 (208.40 to 289.52)254.20 (213.76 to 302.30)193.58 (161.68 to 231.76)80.11 (67.42 to 95.19)
Meningitis Y219.52 (173.10 to 278.39)186.08 (148.25 to 233.55)204.92 (161.40 to 260.16)3.66 (2.86 to 4.69)92.41 (72.75 to 117.37)
Statistical analysis
  • rMenBOMV+ACWY_S Group vs rMenBOMV+ACWY_D Group · ANCOVA · Geometric mean ratio: 1.00 · 80% CI 0.84 to 1.20The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs rMenBOMV+ACWY_D Group · ANCOVA · Geometric mean ratio: 1.05 · 80% CI 0.88 to 1.26The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs rMenBOMV+ACWY_D Group · ANCOVA · Geometric mean ratio: 0.78 · 80% CI 0.64 to 0.95The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs rMenBOMV+ACWY_D Group · ANCOVA · Geometric mean ratio: 0.80 · 80% CI 0.66 to 0.96The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs rMenBOMV+ACWY_D Group · ANCOVA · Geometric mean ratio: 0.92 · 80% CI 0.74 to 1.14The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs rMenBOMV+ACWY_D Group · ANCOVA · Geometric mean ratio: 1.00 · 80% CI 0.78 to 1.27The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs rMenBOMV+ACWY_D Group · ANCOVA · Geometric mean ratio: 0.97 · 80% CI 0.79 to 1.18The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs rMenBOMV+ACWY_D Group · ANCOVA · Geometric mean ratio: 0.91 · 80% CI 0.69 to 1.19The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs rMenBOMV+ACWY_S Group · ANCOVA · Geometric mean ratio: 1.02 · 80% CI 0.86 to 1.22The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs rMenBOMV+ACWY_S Group · ANCOVA · Geometric mean ratio: 0.79 · 80% CI 0.66 to 0.95The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs rMenBOMV+ACWY_S Group · ANCOVA · Geometric mean ratio: 0.79 · 80% CI 0.65 to 0.97The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs rMenBOMV+ACWY_S Group · ANCOVA · Geometric mean ratio: 0.73 · 80% CI 0.60 to 0.88The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs rMenBOMV+ACWY_S Group · ANCOVA · Geometric mean ratio: 0.56 · 80% CI 0.45 to 0.69The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs rMenBOMV+ACWY_S Group · ANCOVA · Geometric mean ratio: 1.19 · 80% CI 0.94 to 1.52The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs rMenBOMV+ACWY_S Group · ANCOVA · Geometric mean ratio: 1.06 · 80% CI 0.87 to 1.29The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs rMenBOMV+ACWY_S Group · ANCOVA · Geometric mean ratio: 1.18 · 80% CI 0.90 to 1.55The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs rMenBOMV Group · ANCOVA · Geometric mean ratio: 1.02 · 80% CI 0.85 to 1.22The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs rMenBOMV Group · ANCOVA · Geometric mean ratio: 0.90 · 80% CI 0.75 to 1.09The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs rMenBOMV Group · ANCOVA · Geometric mean ratio: 0.78 · 80% CI 0.64 to 0.96The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs rMenBOMV Group · ANCOVA · Geometric mean ratio: 0.71 · 80% CI 0.58 to 0.86The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs MenACWY Group · ANCOVA · Geometric mean ratio: 3.60 · 80% CI 2.90 to 4.47The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs MenACWY Group · ANCOVA · Geometric mean ratio: 4.18 · 80% CI 3.28 to 5.31The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs MenACWY Group · ANCOVA · Geometric mean ratio: 3.07 · 80% CI 2.52 to 3.73The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs MenACWY Group · ANCOVA · Geometric mean ratio: 2.01 · 80% CI 1.53 to 2.65The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_D Group vs rMenBOMV Group · ANCOVA · Geometric mean ratio: 1.02 · 80% CI 0.85 to 1.22The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_D Group vs rMenBOMV Group · ANCOVA · Geometric mean ratio: 0.86 · 80% CI 0.71 to 1.04The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_D Group vs rMenBOMV Group · ANCOVA · Geometric mean ratio: 1.01 · 80% CI 0.82 to 1.24The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_D Group vs rMenBOMV Group · ANCOVA · Geometric mean ratio: 0.89 · 80% CI 0.73 to 1.09The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_D Group vs MenACWY Group · ANCOVA · Geometric mean ratio: 3.92 · 80% CI 3.15 to 4.88The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_D Group vs MenACWY Group · ANCOVA · Geometric mean ratio: 4.19 · 80% CI 3.30 to 5.34The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_D Group vs MenACWY Group · ANCOVA · Geometric mean ratio: 3.17 · 80% CI 2.60 to 3.87The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_D Group vs MenACWY Group · ANCOVA · Geometric mean ratio: 2.22 · 80% CI 1.68 to 2.92The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs rMenBOMV Group · ANCOVA · Geometric mean ratio: 1.05 · 80% CI 0.87 to 1.25The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs rMenBOMV Group · ANCOVA · Geometric mean ratio: 0.71 · 80% CI 0.59 to 0.86The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs rMenBOMV Group · ANCOVA · Geometric mean ratio: 0.62 · 80% CI 0.50 to 0.76The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs rMenBOMV Group · ANCOVA · Geometric mean ratio: 0.52 · 80% CI 0.42 to 0.63The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs MenACWY Group · ANCOVA · Geometric mean ratio: 2.02 · 80% CI 1.62 to 2.51The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs MenACWY Group · ANCOVA · Odds ratio (or): 4.99 · 80% CI 3.92 to 6.35The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs MenACWY Group · ANCOVA · Geometric mean ratio: 3.25 · 80% CI 2.66 to 3.96The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs MenACWY Group · ANCOVA · Geometric mean ratio: 2.38 · 80% CI 1.81 to 3.12The model is fitted to each serogroup/strain separately.
PrimaryPercentage of Subjects With hSBA Titers Greater Than or Equal to(≥) the Lower Limit of Quantitation (LLOQ) Against Each of the N. Meningitidis Serogroup B Test Strains and Serogroups A, C, W-135 and Y,One Month After Last Vaccination.

Immune responses against N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y, were calculated in terms of percentage of subjects with hSBA titers ≥ LLOQ. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA).

Time frame:
1 month after last vaccination i.e.: at Day 91 for all groups except the MenACWY Group, and at Day 31 for the MenACWY Group.
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titers Greater Than or Equal to(≥) the Lower Limit of Quantitation (LLOQ) Against Each of the N. Meningitidis Serogroup B Test Strains and Serogroups A, C, W-135 and Y,One Month After Last Vaccination.
Percentage of subjectsMenABCWY GrouprMenBOMV+ACWY_S GrouprMenBOMV+ACWY_D GrouprMenBOMV GroupMenACWY Group
Meningitis B M14459 (fHbp)83.5 (77.64 to 88.28)86.0 (80.50 to 90.35)88.5 (83.22 to 92.57)83.3 (77.18 to 88.31)12.4 (8.21 to 17.78)
Mengitis B 96217(NadA)96.9 (93.31 to 98.87)99.0 (96.17 to 99.89)99.0 (96.05 to 99.89)100.0 (97.47 to 100.00)33.3 (26.96 to 40.24)
Meningitis B NZ98/254 (PorA)59.2 (52.22 to 65.86)76.0 (69.66 to 81.53)80.4 (74.27 to 85.57)78.7 (72.05 to 84.23)5.2 (2.53 to 9.35)
Meningitis B M07-0241084 (NHBA)59.2 (52.22 to 65.86)74.0 (67.54 to 79.71)77.1 (70.66 to 82.62)80.9 (74.48 to 86.22)23.2 (17.57 to 29.64)
Meningitis A94.8 (90.65 to 97.47)100.0 (97.75 to 100.00)99.0 (96.05 to 99.89)91.1 (85.96 to 94.76)68.8 (61.86 to 75.15)
Meningitis C100.0 (97.68 to 100.00)100.0 (97.72 to 100.00)100.0 (97.65 to 100.00)96.7 (92.73 to 98.77)86.6 (81.06 to 90.92)
Meningitis W98.0 (94.66 to 99.46)96.0 (92.17 to 98.24)99.0 (96.01 to 99.89)93.3 (88.59 to 96.46)66.0 (59.09 to 72.36)
Menngitis Y99.0 (96.05 to 99.89)98.0 (94.77 to 99.47)96.9 (93.24 to 98.86)24.7 (18.79 to 31.54)85.4 (79.71 to 89.94)
PrimaryPercentage of Subjects With a 4-fold Increase in hSBA Titers Against Each of the N. Meningitidis Serogroup B Test Strains and Against N. Meningitidis Serogroups A, C, W-135 and Y, One Month After Last Vaccination.

Immune responses against N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y, were calculated in terms of percentage of subjects with a 4-fold increase in hSBA titers. A 4-fold rise was defined as: a) for individuals whose pre-vaccination titers were less than (\<) the limit of detection (LOD), the post-vaccination titers must have been ≥4-fold the LOD or ≥ the LLOQ, whichever was greater; b) for individuals whose pre-vaccination titers were ≥ the LOD and less than (\<) the LLOQ, the post-vaccination titers must have been at least 4 times the LLOQ; and c) for individuals whose pre-vaccination titers were ≥ the LLOQ, the post-vaccination titers must have been at least 4 times the pre-vaccination titer. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA).

Time frame:
1 month after last vaccination versus baseline (i.e.: at Day 91 versus Day 1 for all groups except the MenACWY Group, and at Day 31 versus Day 1 for the MenACWY Group).
Reported as:
Number · Percentage of subjects
Percentage of Subjects With a 4-fold Increase in hSBA Titers Against Each of the N. Meningitidis Serogroup B Test Strains and Against N. Meningitidis Serogroups A, C, W-135 and Y, One Month After Last Vaccination.
Percentage of subjectsMenABCWY GrouprMenBOMV+ACWY_S GrouprMenBOMV+ACWY_D GrouprMenBOMV GroupMenACWY Group
Meningitis B M14459 (fHbp)66.0 (59.09 to 72.36)69.0 (62.32 to 75.09)66.3 (59.36 to 72.74)63.3 (56.09 to 70.11)2.1 (0.55 to 5.39)
Meningitis B 96217(NadA)80.4 (74.27 to 85.57)88.0 (82.74 to 92.04)90.5 (85.46 to 94.20)80.7 (74.20 to 86.06)2.1 (0.56 to 5.45)
Meningitis B NZ98/254 (PorA)48.0 (41.06 to 54.92)60.0 (53.11 to 66.58)58.8 (51.75 to 65.49)60.7 (53.35 to 67.63)1.0 (0.11 to 3.95)
Meningitis B M07-0241084(NHBA)21.4 (16.10 to 27.68)38.8 (32.18 to 45.72)42.1 (35.27 to 49.20)56.3 (48.88 to 63.54)2.1 (0.57 to 5.56)
Meningitis A92.7 (88.04 to 95.90)99.0 (96.17 to 99.89)98.9 (95.97 to 99.89)87.8 (82.14 to 92.06)67.4 (60.34 to 73.85)
Meningitis C90.8 (85.89 to 94.38)91.9 (87.21 to 95.24)86.6 (81.06 to 90.92)57.3 (49.95 to 64.40)52.1 (45.05 to 59.05)
Meningitis W83.3 (77.41 to 88.15)78.6 (72.32 to 83.90)74.2 (67.48 to 80.10)74.1 (67.04 to 80.30)41.1 (34.26 to 48.14)
Meningitis Y95.9 (91.93 to 98.19)91.9 (87.21 to 95.24)93.7 (89.18 to 96.65)11.4 (7.19 to 16.97)76.8 (70.36 to 82.43)
PrimaryhSBA Adjusted Geometric Mean Ratios (GMRs) Against Each of the N. Meningitidis Serogroup B Test Strains and Against N. Meningitidis Serogroups A, C, W-135 and Y, One Month After Last Vaccination.

hSBA mean ratios at 1 month after the last vaccination versus baseline were calculated in terms of GMRs i.e. as the anti-logarithm of the mean of the change from baseline of log-transformed titer values at 1 month after last vaccination and Baseline. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). Adjusted means were obtained from ANCOVA model fitted to each Serogroup (Strain) individually, study group and center as fixed effects and zero-centered pre-vaccination log-transformed titer as a continuous covariate.

Time frame:
1 month after last vaccination versus baseline (i.e.: at Day 91 versus Day 1 for all groups except the MenACWY Group, and at Day 31 versus Day 1 for the MenACWY Group).
Reported as:
Geometric mean · Ratio
hSBA Adjusted Geometric Mean Ratios (GMRs) Against Each of the N. Meningitidis Serogroup B Test Strains and Against N. Meningitidis Serogroups A, C, W-135 and Y, One Month After Last Vaccination.
RatioMenABCWY GrouprMenBOMV+ACWY_S GrouprMenBOMV+ACWY_D GrouprMenBOMV GroupMenACWY Group
Meningitis B M14459 (fHbp)11.17 (9.59 to 13.02)10.90 (9.42 to 12.62)10.85 (9.30 to 12.66)10.69 (9.12 to 12.52)1.16 (0.99 to 1.35)
Meningitis B 96217(NadA)21.33 (18.22 to 24.99)27.02 (23.22 to 31.44)25.66 (21.88 to 30.10)29.87 (25.32 to 35.24)1.09 (0.93 to 1.28)
Meningitis B NZ98/254(PorA)7.28 (6.11 to 8.67)9.20 (7.78 to 10.88)11.85 (9.94 to 14.13)11.77 (9.81 to 14.12)1.21 (1.01 to 1.44)
Meningitis B M07-0241084(NHBA)3.60 (3.05 to 4.25)4.96 (4.23 to 5.81)6.22 (5.27 to 7.35)6.98 (5.87 to 8.30)1.12 (0.95 to 1.33)
Meningitis A33.21 (27.55 to 40.04)59.36 (49.68 to 70.93)64.58 (53.52 to 77.93)30.05 (24.77 to 36.44)16.47 (13.62 to 19.93)
Meningitis C34.34 (27.88 to 42.30)28.74 (23.52 to 35.13)28.86 (23.40 to 35.60)6.35 (5.11 to 7.90)6.88 (5.58 to 8.49)
Meningitis W24.58 (20.72 to 29.15)23.21 (19.69 to 27.36)24.02 (20.20 to 28.56)18.29 (15.28 to 21.90)7.57 (6.37 to 8.99)
Meningitis Y106.87 (84.27 to 135.53)90.59 (72.18 to 113.70)99.76 (78.58 to 126.66)1.78 (1.39 to 2.28)44.99 (35.42 to 57.14)
SecondaryhSBA Adjusted GMTs Against All of N. Meningitidis Serogroup B Test Strains (Pooled), One Month After First Vaccination

hSBA titers against all of N. meningitidis serogroup B test strains were calculated in terms of GMTs. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). The serogroup B strains were grouped together to perform a pooled analysis. Adjusted means were obtained from ANCOVA model fitted to all of the Serogroup B test strains, study group, test strain and center as fixed effects; zero-centered pre-vaccination log-transformed titer was included as a continuous covariate.

Time frame:
1 month after first vaccination i.e.: at Day 31 for all groups except for the MenACWY Group
Reported as:
Geometric mean · Titers
hSBA Adjusted GMTs Against All of N. Meningitidis Serogroup B Test Strains (Pooled), One Month After First Vaccination
TitersMenABCWY GrouprMenBOMV+ACWY_S GrouprMenBOMV+ACWY_D GrouprMenBOMV Group
hSBA Adjusted GMTs Against All of N. Meningitidis Serogroup B Test Strains (Pooled), One Month After First Vaccination6.51 (5.63 to 7.52)8.33 (7.24 to 9.58)8.16 (7.08 to 9.41)9.45 (8.14 to 10.95)
Statistical analysis
  • rMenBOMV+ACWY_S Group vs rMenBOMV+ACWY_D Group · ANCOVA · Geometric mean ratio: 1.02 · 80% CI 0.86 to 1.22An interaction between strain and pre-vaccination log transformed titer is included in the model to fit to the serogroup B test strain data only.
SecondaryhSBA Adjusted GMTs Against Each of the N. Meningitidis Serogroup B Test Strains and N. Meningitidis Serogroups A, C, W-135 and Y, One Month After First Vaccination.

hSBA titers against each of the N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y were calculated in terms of GMTs. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). Adjusted means were obtained from ANCOVA model fitted to each Serogroup (Strain) individually, study group and center as fixed effects and zero-centered pre-vaccination log-transformed titer as a continuous covariate.

Time frame:
1 month after first vaccination i.e.: at Day 31 for all groups except for the MenACWY Group.
Reported as:
Geometric mean · Titers
hSBA Adjusted GMTs Against Each of the N. Meningitidis Serogroup B Test Strains and N. Meningitidis Serogroups A, C, W-135 and Y, One Month After First Vaccination.
TitersMenABCWY GrouprMenBOMV+ACWY_S GrouprMenBOMV+ACWY_D GrouprMenBOMV Group
Meningitis B M14459(fHbp)5.50 (4.55 to 6.66)6.36 (5.29 to 7.65)4.94 (4.09 to 5.96)6.08 (5.00 to 7.39)
Meningitis B 96217 (NadA)8.21 (6.87 to 9.81)11.30 (9.51 to 13.42)12.18 (10.23 to 14.52)14.07 (11.72 to 16.89)
Meningitis B NZ98/254 (PorA)3.79 (3.10 to 4.63)4.83 (3.98 to 5.86)4.76 (3.91 to 5.79)5.48 (4.47 to 6.71)
Meningitis B M07-0241084 (NHBA)6.27 (5.23 to 7.52)7.31 (6.12 to 8.73)6.75 (5.65 to 8.06)7.69 (6.38 to 9.26)
Meningitis A31.38 (24.79 to 39.73)67.95 (54.07 to 85.40)88.29 (69.95 to 111.44)8.22 (6.48 to 10.44)
Meningitis C41.35 (32.39 to 52.79)33.76 (26.61 to 42.85)40.33 (31.71 to 51.29)11.47 (8.92 to 14.74)
Meningitis W108.91 (88.67 to 133.78)81.38 (66.62 to 99.42)92.84 (75.75 to 113.80)42.99 (34.66 to 53.33)
Meningitis Y75.07 (56.86 to 99.13)76.48 (58.31 to 100.32)100.30 (76.13 to 132.15)3.98 (3.00 to 5.30)
Statistical analysis
  • rMenBOMV+ACWY_S Group vs rMenBOMV+ACWY_D Group · ANCOVA · Geometric mean ratio: 1.29 · 80% CI 1.02 to 1.63The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs rMenBOMV+ACWY_D Group · ANCOVA · Geometric mean ratio: 0.93 · 80% CI 0.75 to 1.15The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs rMenBOMV+ACWY_D Group · ANCOVA · Geometric mean ratio: 1.01 · 80% CI 0.80 to 1.29The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs rMenBOMV+ACWY_D Group · ANCOVA · Odds ratio (or): 1.08 · 80% CI 0.87 to 1.36The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs rMenBOMV+ACWY_D Group · ANCOVA · Geometric mean ratio: 0.77 · 80% CI 0.58 to 1.03The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs rMenBOMV+ACWY_D Group · ANCOVA · Geometric mean ratio: 0.84 · 80% CI 0.62 to 1.13The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs rMenBOMV+ACWY_D Group · ANCOVA · Geometric mean ratio: 0.88 · 80% CI 0.68 to 1.13The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs rMenBOMV+ACWY_D Group · ANCOVA · Geometric mean ratio: 0.76 · 80% CI 0.54 to 1.08The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs rMenBOMV+ACWY_S Group · ANCOVA · Geometric mean ratio: 0.87 · 80% CI 0.69 to 1.09The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs rMenBOMV+ACWY_S Group · ANCOVA · Geometric mean ratio: 0.73 · 80% CI 0.58 to 0.90The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs rMenBOMV+ACWY_S Group · ANCOVA · Geometric mean ratio: 0.78 · 80% CI 0.61 to 1.00The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs rMenBOMV+ACWY_S Group · ANCOVA · Geometric mean ratio: 0.86 · 80% CI 0.68 to 1.07The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs rMenBOMV+ACWY_S Group · ANCOVA · Geometric mean ratio: 0.46 · 80% CI 0.35 to 0.62The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs rMenBOMV+ACWY_S Group · ANCOVA · Geometric mean ratio: 1.22 · 80% CI 0.91 to 1.65The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs rMenBOMV+ACWY_S Group · ANCOVA · Geometric mean ratio: 1.34 · 80% CI 1.04 to 1.72The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs rMenBOMV+ACWY_S Group · ANCOVA · Geometric mean ratio: 0.98 · 80% CI 0.70 to 1.38The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs rMenBOMV Group · ANCOVA · Geometric mean ratio: 1.05 · 80% CI 0.83 to 1.32The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs rMenBOMV Group · ANCOVA · Geometric mean ratio: 0.80 · 80% CI 0.64 to 1.00The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs rMenBOMV Group · ANCOVA · Geometric mean ratio: 0.88 · 80% CI 0.69 to 1.13The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_S Group vs rMenBOMV Group · ANCOVA · Geometric mean ratio: 0.95 · 80% CI 0.76 to 1.19The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_D Group vs rMenBOMV Group · ANCOVA · Geometric mean ratio: 0.81 · 80% CI 0.64 to 1.03The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_D Group vs rMenBOMV Group · ANCOVA · Geometric mean ratio: 0.87 · 80% CI 0.69 to 1.09The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_D Group vs rMenBOMV Group · ANCOVA · Geometrical mean ratio: 0.87 · 80% CI 0.68 to 1.12The model is fitted to each serogroup/strain separately.
  • rMenBOMV+ACWY_D Group vs rMenBOMV Group · ANCOVA · Geometrical mean ratio: 0.88 · 80% CI 0.70 to 1.10The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs rMenBOMV Group · ANCOVA · Geometric mean ratio: 0.91 · 80% CI 0.71 to 1.15The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs rMenBOMV Group · ANCOVA · Geometric mean ratio: 0.58 · 80% CI 0.47 to 0.73The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs rMenBOMV Group · ANCOVA · Geometric mean ratio: 0.69 · 80% CI 0.54 to 0.89The model is fitted to each serogroup/strain separately.
  • MenABCWY Group vs rMenBOMV Group · ANCOVA · Geometric mean ratio: 0.82 · 80% CI 0.65 to 1.03The model is fitted to each serogroup/strain separately.
SecondaryPercentage of Subjects With hSBA Titers Greater Than or Equal to (≥) the LLOQ Against Each of the N. Meningitidis Serogroup B Test Strains and Against Serogroups A, C, W-135, and Y, One Month After First Vaccination

Immune responses against N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y, were calculated in terms of percentage of subjects with hSBA titers ≥ LLOQ. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA).

Time frame:
1 month after first vaccination i.e.: at Day 31 for all groups except for the MenACWY Group
Reported as:
Number · Percentage of subjects
Percentage of Subjects With hSBA Titers Greater Than or Equal to (≥) the LLOQ Against Each of the N. Meningitidis Serogroup B Test Strains and Against Serogroups A, C, W-135, and Y, One Month After First Vaccination
Percentage of subjectsMenABCWY GrouprMenBOMV+ACWY_S GrouprMenBOMV+ACWY_D GrouprMenBOMV Group
Meningitis B M14459 (fHbp)36.8 (30.24 to 43.88)49.5 (42.77 to 56.27)37.8 (31.21 to 44.69)42.2 (35.19 to 49.53)
Meningitis B 96217 (NadA)57.3 (50.24 to 64.11)66.0 (59.35 to 72.20)69.4 (62.65 to 75.51)75.8 (69.12 to 81.64)
Meningitis B NZ98/254 (PorA)29.2 (23.08 to 35.93)37.9 (31.48 to 44.61)33.7 (27.35 to 40.51)37.8 (30.94 to 45.04)
Meningitis B M07-0241084 (NHBA)35.1 (28.56 to 42.14)49.5 (42.69 to 56.33)37.5 (30.90 to 44.51)44.4 (37.33 to 51.75)
Meningitis A65.3 (58.28 to 71.75)73.5 (67.12 to 79.22)80.2 (74.01 to 85.41)25.6 (19.58 to 32.38)
Meningitis C89.6 (84.41 to 93.42)94.1 (89.90 to 96.88)92.8 (88.16 to 95.94)70.0 (62.96 to 76.35)
Meningitis W71.9 (65.16 to 77.88)70.6 (64.04 to 76.51)74.2 (67.67 to 80.00)52.3 (44.90 to 59.56)
Meningitis Y83.2 (77.18 to 88.02)81.8 (75.86 to 86.76)88.4 (83.05 to 92.49)20.0 (14.60 to 26.45)
SecondaryPercentage of Subjects With a 4-fold Increase in hSBA Titers Against Each of the N. Meningitidis Serogroup B Test Strains and Against N. Meningitidis Serogroups A, C, W-135, and Y, One Month After First Vaccination

Immune responses against N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y, were calculated in terms of percentage of subjects with a 4-fold increase in hSBA titers. A 4-fold rise is defined as: a) for individuals whose pre-vaccination titers were less than (\<) the limit of detection (LOD), the post-vaccination titers must have been ≥4-fold the LOD or ≥ the LLOQ, whichever was greater; b) for individuals whose pre-vaccination titers were ≥ the LOD and less than (\<) the LLOQ, the post-vaccination titers must have been at least 4 times the LLOQ; and c) for individuals whose pre-vaccination titers were ≥ the LLOQ, the post-vaccination titers must have been at least 4 times the pre-vaccination titer. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA).

Time frame:
1 month after first vaccination versus baseline (i.e.: at Day 31 versus Day 1 for all groups except for the MenACWY Group)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With a 4-fold Increase in hSBA Titers Against Each of the N. Meningitidis Serogroup B Test Strains and Against N. Meningitidis Serogroups A, C, W-135, and Y, One Month After First Vaccination
Percentage of subjectsMenABCWY GrouprMenBOMV+ACWY_S GrouprMenBOMV+ACWY_D GrouprMenBOMV Group
Meningitis B M14459 (fHbp)24.2 (18.52 to 30.76)24.3 (18.80 to 30.53)18.8 (13.67 to 24.86)25.6 (19.58 to 32.38)
Meningitis B 96217 (NadA)22.1 (16.62 to 28.51)34.0 (27.80 to 40.65)30.5 (24.31 to 37.38)32.6 (26.01 to 39.77)
Meningitis B NZ98/254 (PorA)20.8 (15.51 to 27.11)26.2 (20.57 to 32.58)26.8 (20.94 to 33.42)27.8 (21.60 to 34.72)
Meningitis B M07-0241084 (NHBA)9.6 (5.86 to 14.69)20.6 (15.35 to 26.84)13.8 (9.37 to 19.52)20.5 (14.94 to 27.03)
Meningitis A61.7 (54.60 to 68.42)71.3 (64.73 to 77.18)80.6 (74.37 to 85.88)23.3 (17.57 to 30.03)
Meningitis C54.2 (47.11 to 61.09)46.5 (39.78 to 53.39)51.0 (44.02 to 58.03)24.7 (18.79 to 31.54)
Meningitis W60.6 (53.53 to 67.40)52.0 (45.12 to 58.82)51.6 (44.46 to 58.71)39.8 (32.53 to 47.37)
Meningitis Y77.9 (71.49 to 83.38)75.5 (69.06 to 81.14)78.3 (71.76 to 83.79)9.0 (5.30 to 14.19)
SecondaryhSBA Adjusted GMRs Against Each of the N. Meningitidis Serogroup B Test Strains and Against N. Meningitidis Serogroups A, C, W-135, and Y, One Month After First Vaccination

hSBA mean ratios at 1 month after the first vaccination versus baseline were calculated in terms of GMRs. i.e. as the anti-logarithm of the mean of the change from baseline of log-transformed titer values at 1 month after first vaccination and Baseline. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). Adjusted mean were obtained from ANCOVA model fitted to each Serogroup (Strain) individually, study group and center as fixed effects and zero-centered pre-vaccination log-transformed titer as a continuous covariate.

Time frame:
1 month after first vaccination versus baseline (i.e.: at Day 31 versus Day 1 for all groups except for the MenACWY Group)
Reported as:
Geometric mean · Ratio
hSBA Adjusted GMRs Against Each of the N. Meningitidis Serogroup B Test Strains and Against N. Meningitidis Serogroups A, C, W-135, and Y, One Month After First Vaccination
RatioMenABCWY GrouprMenBOMV+ACWY_S GrouprMenBOMV+ACWY_D GrouprMenBOMV Group
Meningitis B M14459 (fHbp)2.59 (2.14 to 3.14)3.00 (2.49 to 3.61)2.33 (1.93 to 2.81)2.87 (2.36 to 3.48)
Meningitis B 96217(NadA)2.15 (1.80 to 2.57)2.96 (2.49 to 3.51)3.19 (2.68 to 3.80)3.68 (3.07 to 4.42)
Meningitis B NZ98/254 (PorA)2.16 (1.77 to 2.64)2.76 (2.27 to 3.34)2.72 (2.23 to 3.31)3.13 (2.55 to 3.83)
Meningitis B M07-0241084 (NHBA)1.73 (1.44 to 2.07)2.01 (1.69 to 2.41)1.86 (1.56 to 2.22)2.12 (1.76 to 2.55)
Meningitis A10.15 (8.02 to 12.85)21.97 (17.48 to 27.62)28.55 (22.62 to 36.04)2.66 (2.09 to 3.38)
Meningitis C8.08 (6.33 to 10.31)6.59 (5.20 to 8.37)7.88 (6.19 to 10.02)2.24 (1.74 to 2.88)
Meningitis W11.08 (9.02 to 13.60)8.28 (6.77 to 10.11)9.44 (7.70 to 11.57)4.37 (3.52 to 5.42)
Meningitis Y36.58 (27.70 to 48.30)37.26 (28.41 to 48.88)48.87 (37.09 to 64.39)1.94 (1.46 to 2.58)
SecondaryNumber of Subjects With Any Solicited Local Adverse Events (AEs)

Assessed local AEs were erythema, swelling, induration and pain. Any erythema, swelling and induration is defined as a symptom with a surface diameter equal to or greater than 25 millimeters.

Time frame:
During the 7 days (including the day of vaccination) after each vaccination i.e after Dose 1 administered at Day 1 (for all groups) and after Dose 2 administered at Day 61 (for all groups except for MenACWY Group)
Reported as:
Count of participants · Participants
Number of Subjects With Any Solicited Local Adverse Events (AEs)
ParticipantsMenABCWY GrouprMenBOMV+ACWY_S GrouprMenBOMV+ACWY_D GrouprMenBOMV GroupMenACWY Group
Erythema at Dose 117191897
Swelling at Dose 12021161310
Induration at Dose 19151264
Pain at Dose 189100958852
Erythema at Dose 215181510—
Swelling at Dose 213141512—
Induration at Dose 26111212—
Pain at Dose 287979587—
SecondaryNumber of Subjects With Any Solicited Systemic AEs

Assessed systemic AEs were arthralgia, fatigue, nausea, headache, myalgia and fever. Any fever is defined as body temperature equal or greater than 38 degrees Celsius.

Time frame:
During the 7 days (including the day of vaccination) after each vaccination i.e after Dose 1 administered at Day 1 (for all groups) and after Dose 2 administered at Day 61 (for all groups except for MenACWY Group)
Reported as:
Count of participants · Participants
Number of Subjects With Any Solicited Systemic AEs
ParticipantsMenABCWY GrouprMenBOMV+ACWY_S GrouprMenBOMV+ACWY_D GrouprMenBOMV GroupMenACWY Group
Arthralgia at Dose 120159918
Fatigue at Dose 15661554650
Nausea at Dose 11623141314
Headache at Dose 14046383636
Myalgia at Dose 13429272128
Fever at Dose 165513
Arthralgia at Dose 222191217—
Fatigue at Dose 258616256—
Nausea at Dose 216131517—
Headache at Dose 252363739—
Myalgia at Dose 241383538—
Fever at Dose 26331—
SecondaryNumber of Subjects With Unsolicited AEs

An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse. An unsolicited AE is an AE that was not solicited using a Subject Diary and that was spontaneously communicated by a subjects/parent(s)/ Legally Acceptable Representative who has signed the informed consent or a solicited local or systemic adverse event that continues beyond the solicited period at day 7 after vaccination.

Time frame:
During the 30 days (including the day of vaccination) after each vaccination i.e after Dose 1 administered at Day 1 (for all groups) and after Dose 2 administered at Day 61 (for all groups except for MenACWY Group)
Reported as:
Count of participants · Participants
Number of Subjects With Unsolicited AEs
ParticipantsMenABCWY GrouprMenBOMV+ACWY_S GrouprMenBOMV+ACWY_D GrouprMenBOMV GroupMenACWY Group
Any unsolicited AEs- Dose 11619161615
Any unsolicited AEs- Dose 211141310—
SecondaryNumber of Subjects With Serious Adverse Events (SAEs), Medically Attended AEs (MAEs), AEs Leading to Withdrawal, and Adverse Events of Special Interest (AESIs)

SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity or was a congenital anomaly/birth defect in the offspring of a study subject. Medically attended AEs are defined as symptoms or illnesses requiring hospitalization, or emergency room visit, or visit to/by a health care provider. AESIs are predefined (serious or non-serious) adverse events of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterize and understand it.

Time frame:
During the whole study period i.e from Day 1 to Day 91
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs), Medically Attended AEs (MAEs), AEs Leading to Withdrawal, and Adverse Events of Special Interest (AESIs)
ParticipantsMenABCWY GrouprMenBOMV+ACWY_S GrouprMenBOMV+ACWY_D GrouprMenBOMV GroupMenACWY Group
SAE(s)02120
MAE(s)141714136
AE(s) leading to withdrawal00000
AESI(s)00000

Adverse events

Collected over Solicited Adverse Events were reported during the 7 days post-vaccination period and Unsolicited Adverse Events during the 30 Days post-vaccination period. Serious Adverse Events: were reported during the whole study period (from Day 1 up to Day 91).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MenABCWY Group0/100 (0%)0/100 (0%)94/100 (94%)
rMenBOMV+ACWY_S Group0/104 (0%)2/104 (1.9%)103/104 (99%)
rMenBOMV+ACWY_D Group0/100 (0%)1/100 (1%)98/100 (98%)
rMenBOMV Group0/94 (0%)2/94 (2.1%)94/94 (100%)
MenACWY Group0/102 (0%)0/102 (0%)80/102 (78.4%)
Most frequent serious events
Most frequent serious events
EventMenABCWY GrouprMenBOMV+ACWY_S GrouprMenBOMV+ACWY_D GrouprMenBOMV GroupMenACWY Group
ConcussionInjury, poisoning and procedural complications0/1002/1040/1000/940/102
Lower limb fractureInjury, poisoning and procedural complications0/1000/1040/1001/940/102
SyncopeNervous system disorders0/1000/1040/1001/940/102
Tibia fractureInjury, poisoning and procedural complications0/1000/1041/1000/940/102
Most frequent other events
Showing 10 of 73
Most frequent other events
EventMenABCWY GrouprMenBOMV+ACWY_S GrouprMenBOMV+ACWY_D GrouprMenBOMV GroupMenACWY Group
Injection site painGeneral disorders94/100102/10497/10093/9453/102
FatigueGeneral disorders70/10074/10472/10063/9450/102
ErythemaGeneral disorders50/10071/10457/10058/9428/102
SwellingGeneral disorders51/10063/10446/10046/9423/102
HeadacheNervous system disorders60/10057/10454/10052/9436/102
IndurationGeneral disorders44/10054/10449/10038/9419/102
MyalgiaMusculoskeletal and connective tissue disorders50/10049/10445/10041/9428/102
ArthralgiaMusculoskeletal and connective tissue disorders29/10029/10418/10019/9418/102
NauseaGastrointestinal disorders24/10026/10426/10026/9414/102
PyrexiaGeneral disorders12/1007/1048/1002/943/102

Baseline characteristics

Age, Continuous
Age, Continuous(Years)MenABCWY GrouprMenBOMV+ACWY_S GrouprMenBOMV+ACWY_D GrouprMenBOMV GroupMenACWY GroupTotal
Mean17.1 ± 4.3416.9 ± 4.2817.1 ± 4.4917.4 ± 4.6417.1 ± 4.5717.1 ± 4.45
Sex: Female, Male
Sex: Female, Male(Participants)MenABCWY GrouprMenBOMV+ACWY_S GrouprMenBOMV+ACWY_D GrouprMenBOMV GroupMenACWY GroupTotal
Female4748495349246
Male5356514153254
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MenABCWY GrouprMenBOMV+ACWY_S GrouprMenBOMV+ACWY_D GrouprMenBOMV GroupMenACWY GroupTotal
Race — WHITE10010410094102500
08

Study locations

1 site
  • GSK Investigational Site
    Hradec Kralove, 50002, Czechia
09

References and documents

Publications

  • Beran J, Drazan D, Enweonye I, Bhusal C, Toneatto D. Immunogenicity and Safety of Investigational MenABCWY Vaccine and of 4CMenB and MenACWY Vaccines Administered Concomitantly or Alone: a Phase 2 Randomized Study of Adolescents and Young Adults. mSphere. 2021 Dec 22;6(6):e0055321. doi: 10.1128/mSphere.00553-21. Epub 2021 Nov 17. PubMed 34787449 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Dec 2018, 5 months.

Results were first posted in Jan 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2018
First posted
Jul 16, 2018
StartActual
Jul 9, 2018
Primary completionActual
Dec 19, 2018
CompletionActual
Dec 19, 2018
Results first posted
Jan 2, 2020
Last update
Feb 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03587207
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 16, 2018
Start date
Jul 9, 2018
Primary completion
Dec 19, 2018
Completion
Dec 19, 2018
Results posted
Jan 2, 2020
Last update
Feb 12, 2020

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline (for GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; Sirtris, a GSK Company; Stiefel, a GSK Company; ViiV Healthcare)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion